An observational study in Glioblastoma and Glioblastoma Multiforme (GBM), sponsored by Royal North Shore Hospital. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Royal North Shore Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Glioblastoma with a site in Australia — 19 open to participants now, 29 under way, 4 of them phase 3. Glioblastoma · Australia.
Among the 68 studies in Glioblastoma with a site in Australia, this one is one of 7 that started in 2025, is one of 3 observational ones, reaches primary completion later than 11 of the 28 other live ones, and was the 63rd registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →19 of the 68 studies in Glioblastoma with a site in Australia are open now. Recruiting first, the newest first:
Eilean Therapeutics · Sites in Australia, Uzbekistan
Ages 18+
Duke University · Sites in Australia, United States
Ages 18+
Filamon LTD · Sites in Australia
Ages 18+
Telix Pharmaceuticals (Innovations) Pty Limited · Sites in Australia, Austria, Belgium and 1 more country
Ages 18+
Nationwide Children's Hospital · Sites in Australia, United States, Canada and 3 more countries
Ages 1–21 · Healthy volunteers
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 25 · Phase 3 14 · Phase 4 1
First in 1999; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 60 across 208 observational studies indexed under Glioblastoma.
Median enrollment 60 across the 64 interventional studies, 20 across the 3 observational. Of the 36 that completed or were terminated, 16 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 68 have an industry lead sponsor. The 10 most frequent:
Royal North Shore Hospital is the lead sponsor of 29 studies on the registry; 10 are open to participants now.
Royal North Shore Hospital has 1 study filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
7 of the studies in Glioblastoma with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03975829Novartis PharmaceuticalsPediatric Long-Term Follow-up and Rollover Study | 2026-11-24 |
| NCT05500612University of SydneyMRI Hypoxia Study for Glioblastoma Multiforme (GBM) Radiation Therapy | 2026-12 |
| NCT05450744Telix Pharmaceuticals (Innovations) Pty Limited131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) | 2027-06 |
| NCT03478462Cellectar Biosciences, Inc.Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas | 2027-06-30 |
| NCT07052877Royal North Shore HospitalThe Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab | 2027-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 68 studies in Glioblastoma with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.
Glioblastoma patients receiving Bevacizumab as part of standard of care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: PSMA PET/CT scan
PSMA PET scan will be used to monitor changes in PSMA expression in response to bevacizumab.
Changes in PSMA PET metabolic tumour volume (MTV) before and after bevacizumab administration.
Time frame: Prior to first administration of bevacizumab to 6 weeks after.
Changes in PSMA PET SUVmax before and after bevacizumab administration.
Time frame: Prior to first administration of bevacizumab to 6 weeks after.
Changes in PSMA PET SUVmean before and after bevacizumab administration.
Time frame: Prior to first administration of bevacizumab to 6 weeks after.
Changes in PSMA PET SUVpeak before and after bevacizumab administration.
Time frame: Prior to first administration of bevacizumab to 6 weeks after.
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Jul 2027, 19 months after the start.
Of 85 non-industry observational studies under Glioblastoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 96. This study's planned 19 months is below that.
Counting every sponsor, half of 100 studies reached it within 52 months; a quarter within 33 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal North Shore Hospital